Yttrium-90 microspheres: Radiation therapy for unresectable liver cancer

Journal of Vascular and Interventional Radiology

Volumn 13, Issue 9 II, 2002, Pages

  Salem, Riad ^a   Thurston, Kenneth G ^a   Carr, Brian I ^a   Goin, James E ^a   Geschwind, Jean Francois H ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Liver neoplasms, therapeutic radiology; Microspheres; Yttrium, radioactive

Indexed keywords

LIVER ENZYME; MICROSPHERE; THERASPHERE; YTTRIUM 90;

BETA RADIATION; CANCER RADIOTHERAPY; CANCER SURGERY; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER TUMOR; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURGICAL ANATOMY; SURVIVAL RATE;

EID: 0036742604     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1051-0443(07)61790-4     Document Type: Review

References (25)

1. Okuda K, Ohtsuki T, Osata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56:918-928.
2. Stefanini GF, Amorati P, Biselli M, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma: an Italian experience. Cancer 1995; 75:2427-2434.
3. Allgaier HP, Diebert P, Olchewski M, et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection: a single-center analysis including 132 patients. Int J Cancer 1998; 79:601-605.
4. Rose AT, Rose, DM, Pinson CW, et al. Hepatocellular carcinoma outcomes based on indicated treatment strategy. Am Surg 1998; 64:1128-1134.
5. Kouromalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998; 42:442-447.
6. Markovic S, Gadzijev E, Stabuc B, et al. Treatment options in western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol 1998; 29:650-659.
7. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578-1583.
8. Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol 1998; 21:386-391.
9. Sithinamsuwan P, Piratvisuth T, Tanomkiat W, Apakupakul N, Tongyoo S. Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. World J Gastroenterol 2000; 6:339-343.
10. Pawarode A, Tangkijvanich P, Voravud N. Outcomes of primary hepatocellular carcinoma treatment: an 8-year experience with 368 patients in Thailand. J Gastroenterol Hepatol 2000; 15: 860-864.
11. Hekele MS, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in central Europe: prognostic features and survival. Gut 2001; 48:103-109.
12. Herold C, Reck T, Fischler P, et al. Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver 2002; 22:23-28.
13. Fong Y, Kemeny N, Lawrence TS. Cancer of the liver and biliary tree. In: De-Vita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology, 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001; 1162-1203.
14. Marcos-Alverez A, Jenkins RL, Washburn K, et al. Multi-modality treatment of hepatocellular carcinoma in a hepatobiliary center. Arch Surg 1996; 131:292-298.
15. Mazzaferro V, Regalla E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:696-699.
16. Selby R, Kadry Z, Carr B, Tzakis A, Madariaga JR, Iwatsuki S. Liver transplantation for hepatocellular carcinoma. World J Surg 1995; 19:53-58.
17. Lawrence TS, Dworzanin LM, Walker-Andrews SC, et al. Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys 1991; 20:555-561.
18. McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, Lawrence TS. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 1998; 16:2246-2252.
19. Dawson LA, McGinn NJ, Ensminger W, et al. Preliminary results of escalated focal liver radiation and hepatic artery floxuridine for unresectable liver malignancies (abstr). Proc Am Soc Clin Oncol 1999; 18(suppl);86.
20. Houle S, Yip TK, Shepherd FA, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989; 172:857-860.
21. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology 1988; 169:311-314.
22. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35:1637-1644.
23. Marn, CS, Andrews JC, Francis IR, Holett MD, Walker SC, Ensminger WD. Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings. Radiology 1993; 187:125-128.
24. 90Y microspheres. J Nucl Med 2000; 41:1673-1681.
25. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Intervent Radiol 2001; 12:321-326.